TY - JOUR
T1 - Baseline Characteristics of Elderly Japanese Patients Aged ≥75 Years With Non-Valvular Atrial Fibrillation and a History of Stroke ― ANAFIE Registry ―
AU - All Nippon Atrial Fibrillation in the Elderly (ANAFIE) Group
AU - Kanemaru, Kodai
AU - Yoshimoto, Takeshi
AU - Inoue, Hiroshi
AU - Yamashita, Takeshi
AU - Akao, Masaharu
AU - Atarashi, Hirotsugu
AU - Ikeda, Takanori
AU - Okumura, Ken
AU - Koretsune, Yukihiro
AU - Shimizu, Wataru
AU - Tsutsui, Hiroyuki
AU - Hirayama, Atsushi
AU - Yasaka, Masahiro
AU - Yamaguchi, Takenori
AU - Teramukai, Satoshi
AU - Kimura, Tetsuya
AU - Kaburagi, Jumpei
AU - Takita, Atsushi
AU - Kusano, Kengo
AU - Toyoda, Kazunori
N1 - Publisher Copyright:
© 2020 Japanese Circulation Society. All rights reserved.
PY - 2020/3
Y1 - 2020/3
N2 - Background: Despite the well-established benefits in patients with non-valvular atrial fibrillation (NVAF), oral anticoagulants (OAC) have been underused in elderly patients. We investigated the characteristics and status of anti-thrombotic therapy in elderly NVAF patients in Japan according to a history of stroke or of transient ischemic attack (TIA). Methods and Results: In a multicenter, prospective, observational study, 32,726 Japanese patients aged ≥75 years with NVAF were enrolled, and divided into 3 groups for the present analysis: 6,543 patients with previous ischemic stroke (IS) or TIA (2,410 women), 275 with previous hemorrhagic stroke (HS; 113 women), and the other 25,908 without previous stroke or TIA (11,470 women). Median CHADS2 score was 5 in patients with IS/TIA, 2 in those with HS and 2 in those without stroke/TIA (P<0.05). Anti-thrombotic agents were used in 97.1% of patients with IS/TIA (OAC alone in 73.0%; antiplatelets alone in 3.7%; and both in 23.4%), 90.2% of those with HS (84.7%, 3.2%, and 12.1%, respectively), and 94.1% of those without stroke/TIA (83.4%, 2.7%, and 13.9%, respectively; P<0.05 for any anti-thrombotic choice). Of patients taking OAC, 72.2% received direct OAC (DOAC). Conclusions: In this unique nationwide NVAF registry of >30,000 elderly patients, >90% of patients, even those with HS, received anti-thrombotic therapy, nearly always with OAC. DOAC were the major choice of OAC.
AB - Background: Despite the well-established benefits in patients with non-valvular atrial fibrillation (NVAF), oral anticoagulants (OAC) have been underused in elderly patients. We investigated the characteristics and status of anti-thrombotic therapy in elderly NVAF patients in Japan according to a history of stroke or of transient ischemic attack (TIA). Methods and Results: In a multicenter, prospective, observational study, 32,726 Japanese patients aged ≥75 years with NVAF were enrolled, and divided into 3 groups for the present analysis: 6,543 patients with previous ischemic stroke (IS) or TIA (2,410 women), 275 with previous hemorrhagic stroke (HS; 113 women), and the other 25,908 without previous stroke or TIA (11,470 women). Median CHADS2 score was 5 in patients with IS/TIA, 2 in those with HS and 2 in those without stroke/TIA (P<0.05). Anti-thrombotic agents were used in 97.1% of patients with IS/TIA (OAC alone in 73.0%; antiplatelets alone in 3.7%; and both in 23.4%), 90.2% of those with HS (84.7%, 3.2%, and 12.1%, respectively), and 94.1% of those without stroke/TIA (83.4%, 2.7%, and 13.9%, respectively; P<0.05 for any anti-thrombotic choice). Of patients taking OAC, 72.2% received direct OAC (DOAC). Conclusions: In this unique nationwide NVAF registry of >30,000 elderly patients, >90% of patients, even those with HS, received anti-thrombotic therapy, nearly always with OAC. DOAC were the major choice of OAC.
UR - http://www.scopus.com/inward/record.url?scp=85094932034&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094932034&partnerID=8YFLogxK
U2 - 10.1253/circj.CJ-19-0974
DO - 10.1253/circj.CJ-19-0974
M3 - Article
C2 - 31983727
AN - SCOPUS:85094932034
SN - 1346-9843
VL - 84
SP - 516
EP - 523
JO - Circulation Journal
JF - Circulation Journal
IS - 3
ER -